Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gastroenterology | Internal Medicine | Nursing | Oncology | Pathology | Pharmacy | Journal

Back to Journal Articles

Aspirin Improves Survival for CRC With PIK3CA Mutation

Last Updated: October 24, 2012.

 

Use of aspirin after diagnosis ups cancer-specific, overall survival for patients with mutated PIK3CA

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Among patients with colorectal cancer, regular use of aspirin after diagnosis is associated with longer survival for those with the mutated phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene, according to a study published in the Oct. 25 issue of the New England Journal of Medicine.

WEDNESDAY, Oct. 24 (HealthDay News) -- Among patients with colorectal cancer (CRC), regular use of aspirin after diagnosis is associated with longer survival for those with the mutated phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene (PIK3CA), according to a study published in the Oct. 25 issue of the New England Journal of Medicine.

Xiaoyun Liao, M.D., Ph.D., from the Dana-Farber Cancer Institute in Boston, and colleagues analyzed data for 964 patients with rectal or colon cancer participating in the Nurses' Health Study and the Health Professionals Follow-up Study, including data on aspirin use after diagnosis and PIK3CA mutation status.

Among patients with mutated-PIK3CA CRCs, the researchers found that regular use of aspirin after diagnosis correlated with significantly improved CRC-specific survival (multivariate hazard ratio [HR] for cancer-related death, 0.18) and overall survival (multivariate HR for death from any cause, 0.54). Among patients with wild-type PIK3CA cancers, there was no correlation for regular use of aspirin after diagnosis with CRC-specific survival (multivariate HR, 0.96; 95 percent confidence interval [CI], 0.69 to 1.32) or overall survival (multivariate HR, 0.94; 95 percent CI, 0.75 to 1.17).

"Regular use of aspirin after diagnosis was associated with longer survival among patients with mutated-PIK3CA CRC, but not among patients with wild-type PIK3CA cancer," the authors write. "The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in CRC may serve as a predictive molecular biomarker for adjuvant aspirin therapy."

One author disclosed financial ties to several pharmaceutical companies.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: ASRM: Dietary Glycemic Load Linked to Sperm Concentration Next: Terminal Cancer Patients May Have Erroneous Chemo Beliefs

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.